Daniel Burgess

Daniel D.
Burgess was the founder of Rempex Pharmaceuticals, Inc., founded in 2011, where the titles held included President, Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Pulmocide Ltd., President & Chief Executive Officer at Tripex Pharmaceuticals LLC since 2014, Chairman at Qpex Biopharma, Inc., Director at Leiter's Enterprises, Inc., Director at Leiters, Inc., and Director at Therini Bio, Inc. since 2021.
Former jobs include President & Chief Executive Officer at MPEX Pharmaceuticals, Inc. from 2007 to 2011, Chairman-Supervisory Board at Nabriva Therapeutics GmbH from 2016 to 2017, Chairman at Atox Bio Ltd., Chairman at Nabriva Therapeutics Plc, Chairman at Biocom, Inc. from 2017 to 2019, Independent Director at Santarus, Inc. from 2011 to 2014, Director at Metabasis Therapeutics, Inc. from 2004 to 2010, Director at Arsanis, Inc., Independent Director at Cidara Therapeutics, Inc. from 2014 to 2026, Director at Avalyn Pharma Inc., Independent Director at Arbutus Biopharma Corp.
from 2017 to 2025, Principal at Castle & Cooke, Inc., Chief Operating & Financial Officer at Harbor Diversified, Inc. from 1999 to 2007, Chief Financial Officer & Vice President at Ngen, Inc. from 1998 to 2007, Chief Financial Officer & Vice President at SICOR, Inc., Venture Partner at SV Health Investors LLC, Financial Analyst at Smith Barney Harris Upham & Co., Inc., President at Gensia Automedics, Inc., and Chief Operating & Financial Officer at Hollis Eden Pharmaceuticals.
Education includes undergraduate studies at Stanford University and an MBA from Harvard Business School.